Suchen
Pharvaris NV
PHVSZur Watchlist hinzufügen
29.879USD
-0.821-2.67%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.95BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Pharvaris NV Unternehmen
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV Informationen
BörsenkürzelPHVS
Name des UnternehmensPharvaris NV
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
AddresseEmmy Noetherweg 2
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 BK
Telefon31712036410
Websitehttps://pharvaris.com/
BörsenkürzelPHVS
IPO-datumFeb 05, 2021
CEOModig (Berndt B.A.E)
Führungskräfte von Pharvaris NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.28K
-5.73%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-1.57%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
201.62K
+99.60%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
+54.39%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
106.11K
+48.26%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Feb 19
Aktualisiert: Thu, Feb 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
Andere
60.52%
Aktionäre
Aktionäre
Anteil
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
Andere
60.52%
Aktionärstypen
Aktionäre
Anteil
Private Equity
31.30%
Hedge Fund
20.13%
Investment Advisor
18.48%
Investment Advisor/Hedge Fund
10.17%
Venture Capital
4.94%
Individual Investor
4.89%
Research Firm
0.63%
Pension Fund
0.07%
Bank and Trust
0.07%
Andere
9.33%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
165
59.26M
90.60%
-451.33K
2025Q4
152
61.74M
96.38%
+11.01M
2025Q3
118
49.64M
77.50%
-950.63K
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
General Atlantic LLC
8.03M
12.54%
--
--
Dec 31, 2025
Fidelity Management & Research Company LLC
6.40M
9.99%
--
--
Dec 31, 2025
Foresite Capital Management, LLC
4.78M
7.46%
--
--
Dec 31, 2025
VenBio Partners LLC
4.64M
7.24%
--
--
Dec 31, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Dec 31, 2025
EQT Partners AB
3.42M
5.35%
--
--
Dec 31, 2025
Deerfield Management Company, L.P.
3.13M
4.88%
+683.58K
+27.99%
Dec 31, 2025
Bain Capital Life Sciences Investors, LLC
2.80M
4.37%
-379.19K
-11.92%
Dec 31, 2025
Wellington Management Company, LLP
1.91M
2.98%
+171.05K
+9.86%
Dec 31, 2025
Commodore Capital LP
1.89M
2.95%
-529.03K
-21.87%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ALPS Medical Breakthroughs ETF
0.59%
iShares MSCI Netherlands ETF
0.23%
SPDR S&P International Small Cap ETF
0.08%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.87%
ALPS Medical Breakthroughs ETF
Anteil0.59%
iShares MSCI Netherlands ETF
Anteil0.23%
SPDR S&P International Small Cap ETF
Anteil0.08%
iShares MSCI Europe Small-Cap ETF
Anteil0.04%
iShares MSCI EAFE Small-Cap ETF
Anteil0.02%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Anteil0.01%
Avantis International Small Cap Equity ETF
Anteil0%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
